Officer and Director Stock Option Grant

Maha Radhakrishnan, a director at Candel Therapeutics, Inc., was granted 32,000 stock options on June 23, 2026. These options, exercisable at $9.08 per share, are for the company's Common Stock and vest over time, with full vesting possible by June 23, 2027, or the next Annual Meeting of Stockholders, subject to continued service as a director. The options expire on June 23, 2036. This transaction is reported on Form 4.